PVX-410 / OncoPep 
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PVX-410 / OncoPep
NCT04634747: Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

Not yet recruiting
2
53
NA
PVX-410
OncoPep, Inc.
Metastatic Triple-Negative Breast Carcinoma
04/23
04/25
NCT02826434: Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Active, not recruiting
1
22
US
PVX-410, Durvalumab, MEDI4736, Hiltonol, poly-ICLC
Massachusetts General Hospital, OncoPep, Inc., AstraZeneca
Breast Cancer
06/24
09/25
NCT02886065: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Active, not recruiting
1
19
US
Hiltonol, Poly ICLC, Citarinostat, CC-96241, Lenalidomide, REVLIMID, PVX-410
Massachusetts General Hospital, Celgene, OncoPep, Inc.
Smoldering Multiple Myeloma
09/24
09/24
NCT03362060: PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Active, not recruiting
1
20
US
Pembrolizumab, Keytruda, PVX-410
Massachusetts General Hospital, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer, Metastatic Breast Cancer
06/24
12/25

Download Options